Not Signed In -
Magnesium |
|
|
Clinical Trial: Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
This study is no longer recruiting patients.
|
Purpose
This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Zollinger-Ellison Syndrome | Drug: Esomeprazole magnesium | Phase III |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Digestive Diseases; Peptic Ulcer; Stomach Disorders
Study Type: Interventional
Study Design: Treatment, Open Label
Official Title: A Phase III, Multicenter, Open-Label Study To Evaluate the Control of Gastric Acid Secretion with Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome For 12 Months
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Males or females at least 18 years of age.
- Diagnosis of Zollinger-Ellison Syndrome or idiopathic hypersecretion
Exclusion Criteria:
- Pregnant or lactating females
- History of drug addiction or alcohol abuse within 12 months prior to Screening.
- History of intolerance to any proton pump inhibitors or any ingredient in their formulation.
Location Information
California
Research Site, Los Angeles, California, United States
Florida
Research Site, Gainesville, Florida, United States
Pennsylvania
Research Site, Philadelphia, Pennsylvania, United States
France
Research Site, Paris, France
More Information
Record last reviewed: March 2005
Last Updated: March 14, 2005
Record first received: March 16, 2004
ClinicalTrials.gov Identifier: NCT00079833
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
